Free Trial

Chemed (CHE) Competitors

Chemed logo
$554.75 +4.76 (+0.87%)
(As of 11/7/2024 ET)

CHE vs. LH, DGX, DVA, CRVL, RCM, AMED, AMN, MD, CCRN, and OPCH

Should you be buying Chemed stock or one of its competitors? The main competitors of Chemed include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), CorVel (CRVL), R1 RCM (RCM), Amedisys (AMED), AMN Healthcare Services (AMN), Pediatrix Medical Group (MD), Cross Country Healthcare (CCRN), and Option Care Health (OPCH).

Chemed vs.

Chemed (NYSE:CHE) and Laboratory Co. of America (NYSE:LH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Laboratory Co. of America received 284 more outperform votes than Chemed when rated by MarketBeat users. Likewise, 63.93% of users gave Laboratory Co. of America an outperform vote while only 63.53% of users gave Chemed an outperform vote.

CompanyUnderperformOutperform
ChemedOutperform Votes
331
63.53%
Underperform Votes
190
36.47%
Laboratory Co. of AmericaOutperform Votes
615
63.93%
Underperform Votes
347
36.07%

Chemed currently has a consensus price target of $641.50, suggesting a potential upside of 15.64%. Laboratory Co. of America has a consensus price target of $255.92, suggesting a potential upside of 7.04%. Given Chemed's stronger consensus rating and higher probable upside, equities analysts clearly believe Chemed is more favorable than Laboratory Co. of America.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chemed
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Laboratory Co. of America
0 Sell rating(s)
4 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.80

Chemed has a net margin of 12.69% compared to Laboratory Co. of America's net margin of 3.43%. Chemed's return on equity of 27.86% beat Laboratory Co. of America's return on equity.

Company Net Margins Return on Equity Return on Assets
Chemed12.69% 27.86% 19.12%
Laboratory Co. of America 3.43%15.27%7.13%

Chemed has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

Chemed pays an annual dividend of $2.00 per share and has a dividend yield of 0.4%. Laboratory Co. of America pays an annual dividend of $2.88 per share and has a dividend yield of 1.2%. Chemed pays out 10.1% of its earnings in the form of a dividend. Laboratory Co. of America pays out 55.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has raised its dividend for 16 consecutive years.

In the previous week, Chemed had 3 more articles in the media than Laboratory Co. of America. MarketBeat recorded 15 mentions for Chemed and 12 mentions for Laboratory Co. of America. Laboratory Co. of America's average media sentiment score of 1.12 beat Chemed's score of 0.45 indicating that Laboratory Co. of America is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Chemed
4 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Laboratory Co. of America
8 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

95.9% of Chemed shares are held by institutional investors. Comparatively, 95.9% of Laboratory Co. of America shares are held by institutional investors. 3.3% of Chemed shares are held by insiders. Comparatively, 0.9% of Laboratory Co. of America shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Laboratory Co. of America has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemed$2.26B3.69$272.51M$19.7928.03
Laboratory Co. of America$12.16B1.64$418M$5.1746.25

Summary

Chemed and Laboratory Co. of America tied by winning 11 of the 22 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHE vs. The Competition

MetricChemedHome health care services IndustryMedical SectorNYSE Exchange
Market Cap$8.35B$2.98B$5.28B$20.00B
Dividend Yield0.38%0.38%5.10%3.56%
P/E Ratio28.0322.43117.8941.42
Price / Sales3.691.221,384.1517.45
Price / Cash21.3815.9738.9117.31
Price / Book6.762.684.905.26
Net Income$272.51M-$57.02M$118.16M$988.95M
7 Day Performance2.64%8.16%4.41%4.34%
1 Month Performance-4.07%6.26%10.21%3.49%
1 Year Performance-4.36%45.80%37.59%29.50%

Chemed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CHE
Chemed
4.8961 of 5 stars
$554.75
+0.9%
$641.50
+15.6%
-4.4%$8.28B$2.38B28.0315,087Analyst Forecast
LH
Laboratory Co. of America
4.8766 of 5 stars
$239.10
+2.0%
$255.92
+7.0%
+15.5%$20.00B$12.16B46.2567,000Positive News
DGX
Quest Diagnostics
4.93 of 5 stars
$156.20
+0.7%
$164.58
+5.4%
+17.5%$17.43B$9.25B20.9948,000Analyst Downgrade
Insider Selling
Positive News
DVA
DaVita
4.3151 of 5 stars
$150.37
+2.2%
$161.80
+7.6%
+87.8%$12.06B$12.14B16.2270,000
CRVL
CorVel
0.9893 of 5 stars
$353.14
+0.6%
N/A+78.5%$6.05B$795.31M78.304,870Gap Up
RCM
R1 RCM
2.8702 of 5 stars
$14.28
+0.1%
$15.41
+7.9%
+31.9%$6.03B$2.25B-142.8030,000Earnings Report
AMED
Amedisys
3.7799 of 5 stars
$96.80
-0.9%
$100.67
+4.0%
+4.8%$3.12B$2.24B34.5719,000Earnings Report
Upcoming Earnings
AMN
AMN Healthcare Services
4.8309 of 5 stars
$40.90
-0.7%
$58.20
+42.3%
-35.0%$1.46B$3.79B15.793,585Gap Up
MD
Pediatrix Medical Group
1.8319 of 5 stars
$16.03
-0.3%
$16.10
+0.4%
+62.2%$1.38B$1.99B-5.245,170Earnings Report
Analyst Forecast
CCRN
Cross Country Healthcare
4.8221 of 5 stars
$12.27
+1.0%
$18.50
+50.8%
-33.4%$414.85M$2.02B53.3510,831Earnings Report
Analyst Forecast
OPCH
Option Care Health
4.8831 of 5 stars
$22.93
-2.4%
$30.83
+34.5%
-19.8%$3.90B$4.30B19.277,802Gap Down

Related Companies and Tools


This page (NYSE:CHE) was last updated on 11/8/2024 by MarketBeat.com Staff
From Our Partners